Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Veracyte Inc VCYT

Healthcare Biotechnology
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and assure patients. The Company offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory... see more

Recent & Breaking News (NDAQ:VCYT)

Veracyte to Participate in Upcoming Investor Conferences

Business Wire May 23, 2023

Veracyte Announces that New Data Show Use of the Prosigna Test Significantly Changed Treatment Decisions for Patients with Early-Stage Breast Cancer

Business Wire May 12, 2023

Veracyte Announces First Quarter 2023 Financial Results

Business Wire May 4, 2023

New Data Being Presented at AACE 2023 Help Elucidate Cancer Risk of TERT Promoter Gene Mutations in Patients with Indeterminate Thyroid Nodules

Business Wire May 4, 2023

New Data Published In Cancer Suggest Decipher GRID-Derived Gene Expression Signature Could Enable More Personalized Treatment for Prostate Cancer Patients

Business Wire May 3, 2023

Veracyte Announces Release of Inaugural ESG Report

Business Wire May 3, 2023

Data Published in "The Red Journal" Validate Clinical Utility of Veracyte's Decipher Prostate Genomic Classifier To Help Guide Therapy in Men with Intermediate-Risk Prostate Cancer

Business Wire May 2, 2023

Three Abstracts Focusing on the Clinical Utility of Veracyte's Genomic Tests in ILD and Lung Cancer To Be Presented at ATS 2023 International Conference

Business Wire May 1, 2023

Findings From Two Large-Scale, Real-World Data Sets Reinforce Clinical Utility of Veracyte's Decipher Prostate Genomic Classifier

Business Wire April 29, 2023

Veracyte Announces Five Abstracts Providing Molecular Insights Into Prostate and Other Cancers To Be Presented at the 2023 ASCO Annual Meeting

Business Wire April 27, 2023

New Data Reinforce Ability of Veracyte's Decipher Prostate Genomic Classifier To Help Identify Prostate Cancer Patients Who Would Benefit from Treatment Intensification

Business Wire April 17, 2023

Veracyte to Release First Quarter 2023 Financial Results on May 4, 2023

Business Wire April 13, 2023

Veracyte Announces Seven Abstracts for Its Decipher Urologic Cancer Tests To Be Presented at 2023 AUA Annual Meeting

Business Wire April 12, 2023

Veracyte Announces Three Abstracts to Be Presented at AACR Annual Meeting 2023 Highlighting the Company's Multi-Omics Capabilities and Tools for Biopharma Partners

Business Wire March 15, 2023

Veracyte Provides Statement on Impact of Events Surrounding Silicon Valley Bank

Business Wire March 11, 2023

Veracyte to Participate in Upcoming Investor Conferences

Business Wire February 27, 2023

Veracyte Announces Fourth Quarter and Full-Year 2022 Financial Results

Business Wire February 22, 2023

Data Published in "The Red Journal" Validate Prognostic Value of Veracyte's Decipher Prostate Genomic Classifier for Men with High-Risk Prostate Cancer

Business Wire February 15, 2023

New Data To Be Presented at 2023 ASCO GU Suggest Decipher GRID-Derived Gene Expression Signature Can Help Personalize Prostate Cancer Treatment

Business Wire February 13, 2023

Veracyte to Release Fourth Quarter and Full-Year 2022 Financial Results on February 22, 2023

Business Wire February 6, 2023